Clinical trials: Non-Hodgkin-Lymphoma
Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
huCART19-IL18 in CD19+ Cancers
The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.
- Conditions
- Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
- Trial name
- NCT04684563
- Testing
- huCART19-IL18
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Pennsylvania
Lymphoma
Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002576
- Testing
- cyclophosphamide, doxorubicin hydrochloride, mitoxantrone hydrochloride
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Lymphoma, B-cell Lymphoma
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Sometimes researchers change the DNA (genetic material in cells) of donated T cells (white blood cells that support the immune system) using a process called "gene transfer." Gene transfer involves drawing blood from the patient…
- Trial name
- NCT00968760
- Testing
- Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma Refractory
Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
The goal of this open, single-arm practical, phase II, clinical study is to evaluate the efficacy and safety of the mitoxantrone hydrochloride liposome injection-containing regimens in bridging therapies of CD19 CAR-T cells.
- Trial name
- NCT06220097
- Testing
- Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Hepatic Impairment
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389
The purpose of this study is to examine the safety and tolerability of AZD2389 in participants with hepatic impairment and participants with normal hepatic function.
- Trial name
- CAMPOLINA (NCT06812780)
- Testing
- AZD2389
- Where
- 5 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory
MB-CART19.1 in Patients With R/R ALL
Precursor-B acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Despite major advances in ALL therapy, 20% of children and 40-50% of adults fail state-of-the art first-line treatment.
- Trial name
- NCT03321123
- Testing
- MB-CART19.1
- Volunteers
- 10 people
- Sponsor
- Shanghai Children's Medical Center
Follicular Lymphoma
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Follicular lymphoma (FL) is an indolent yet incurable lymphoma characterized by initial responses to standard therapies, invariably followed by shorter disease free intervals.
- Trial name
- NCT02877550
- Testing
- Obinutuzumab, Venetoclax
- Where
- 6 sites in Switzerland
- Volunteers
- 25 people
- Sponsor
- Swiss Cancer Institute
Malignant Lymphoma, Hodgkin's Disease
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
Background: The malignant lymphomas, Hodgkin´s disease (HD) and non-Hodgkin´s lymphoma (NHL), comprise approximately 5-6% of all malignancies in adults and account for 10% of childhood cancers.
- Conditions
- Malignant Lymphoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Trial name
- NCT00685997
- Where
- 3 sites in Netherlands
- Volunteers
- 135 people
- Sponsor
- UMC Utrecht
CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.
- Conditions
- CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis, Mycosis Fungoides
- Trial name
- NCT01352520
- Testing
- SGN-35
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin's Lymphoma, Hodgkins Disease
Autologous and Allogeneic Transplant for Relapsed Lymphoma
The sequential combination of myeloablative therapy and autologous stem cell transplantation (APBSCT) followed by a reduced intensity allogeneic stem cell transplant (Allo SCT) and post SCT adoptive cellular immunotherapy will be…
- Trial name
- NCT00802113
- Testing
- Fludarabine, Busulfan, Anti-Thymocyte Globulin
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Columbia University
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00335140
- Testing
- Rituximab, Cytarabine, Dexamethasone
- Where
- 68 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer)
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells.
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer
- Trial name
- NCT07555210
- Testing
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jessica Mezzanotte Sharpe
Mantle Cell Lymphoma, COVID-19
A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole
This Phase 1 study is being conducted to support the clinical development of acalabrutinib in hospitalized patients who are unable to swallow acalabrutinib tablet or capsule due to respiratory failure, eg, they may require…
- Trial name
- NCT04564040
- Testing
- Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific…
- Conditions
- Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma
- Trial name
- NCT05544968
- Testing
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Medical College of Wisconsin
Dementia, Mild, Dementia of Alzheimer Type
Adaptation of the Uniform Data Set for Telematic Administration
The present project is an evolution of the previous RIN 2019 study aimed at validating and standardizing the Uniform Data Set (UDS) for dementia, a battery of tests exploring various cognitive domains (memory, language, praxis…
- Trial name
- NCT05785910
- Testing
- IUDS
- Where
- Italy
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymphoma, Extranodal NK-T-Cell
MESA Treatment for NK/T Cell Lymphoma
Study on the efficacy and safety of MESA chemotherapy for treating NK/T cell lymphoma
- Trial name
- MTN (NCT01933282)
- Testing
- MESA chemotherapy, MESA
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Air Force Military Medical University, China
Diffuse, Large B-Cell, Lymphoma
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.
- Trial name
- GIOTTO (NCT02374424)
- Testing
- GA101_DHAP
- Where
- 10 sites in Italy
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Fondazione Italiana Linfomi - ETS
Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Sorafenib may stop the growth of cancer cells by blocking blood flow to the cancer and by blocking some of the enzymes needed for cell growth.
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00278382
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.